About US
Contact us
-
After Xiidra deal with Bausch, Novartis divests Indian eye care brands to J.B. Pharma for $116MLast year, reports surfaced that Novartis—hot off the heels of a planned restructuring and spinoff of generics giant Sandoz—was further weighing a sale for its ophthalmology business. Now, after a si2023/12/12
-
UPDATED: As Stelara cliff looms, J&J expects 25 blockbuster drugs to drive future sales growthAs Johnson & Johnson places a magnifying glass on its pharmaceutical business, the focus for the remainder of the decade rests on the shoulders of some 25 new and upcoming drugs. Together, those2023/12/8
-
In letter to lawmakers, cancer patient advocates call for more action in fighting drug shortagesAs the year comes to a close, shortages of key cancer drugs have no end in sight. Joining the effort to push legislators to respond, the American Cancer Society Cancer Action Network (ACS CAN) illust2023/12/8
-
Pfizer site in Connecticut in line for layoffs amid $3.5B cost-cutting campaignWith layoffs hitting employees on both sides of the Atlantic, Pfizer’s $3.5 billion cost-cutting spree has kicked it into high gear this month. Now, the company’s Groton, Connecticut, site is the lat2023/12/5
-
SABCS: Handing Novartis a win, Lilly's Verzenio barely misses overall survival goal in first-line breast cancerNovartis’ Kisqali is getting a leg up in the CDK4/6 breast cancer realm as another rival failed to significantly extend patients’ lives in a pivotal trial. A phase 3 study testing Eli Lilly’s Verzeni2023/12/5
-
FDA endorses Novartis' 'pipeline in a pill,' granting first nod for potential blockbuster FabhaltaNovartis has gained the first of what it hopes are several FDA approvals for its factor B inhibitor iptacopan,dubbedtwo months ago “a pipeline in pill,” by analysts at ODDO BHF. The United States reg2023/11/30
-
Daiichi Sankyo scores $182M from Novartis settlement in long-running patent caseAfter years of back and forth with Daiichi Sankyo over cancer drug patent claims, Novartis has thrown in the towel with a $182 million settlement. The case stems back to2017and has its roots in Novar2023/11/30
-
For Merck, Lynparza fails to improve on Keytruda in first-line lung cancerMerck has called it quits on another attempt to enhance its powerful PD-1 inhibitor Keytruda in non-small cell lung cancer (NSCLC). Adding AstraZeneca-partnered Lynparza to Keytruda as a maintenance2023/11/28
-
Novartis hit with FDA letter detailing 'significant' Kymriah manufacturing shortfallsWhen it comes to manufacturing cell therapies, it's often said that the "process is the product." But churning out these complex, individualized drugs has routinelytripped up even the industry's larg2023/11/28
-
Lilly's Jaypirca blazes leukemia trail with FDA nod, fast confirmatory trial filingAs AbbVie, Johnson & Johnson,AstraZeneca and BeiGene are battling it out in the same BTK inhibitor market, Eli Lilly is trailblazing a new path for the blood cancer drug class. On Friday, Dec.1,2023/11/23